Vinorelbine
- Generic Name
- Vinorelbine
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C45H54N4O8
- CAS Number
- 71486-22-1
- Unique Ingredient Identifier
- Q6C979R91Y
- Background
Vinorelbine is an anti-mitotic chemotherapy drug that is used in the treatment of several types of malignancies, including breast cancer and non-small cell lung cancer (NSCLC) . It was initially approved in the USA in 1990's for the treatment of NSCLC .
...
- Indication
Vinorelbine tartrate is indicated for adults in the treatment of advanced non-small cell lung cancer (NSCLC), as a single therapy or in combination with other chemotherapeutic drugs .
Used in relapsed or refractory Hodgkin lymphoma, in combination with other chemotherapy agents .
...
- Associated Conditions
- Locally Advanced Non-Small Cell Lung Cancer, Metastatic Breast Cancer, Metastatic Cervical Cancer, Metastatic Non-Small Cell Lung Cancer, Recurrent Cervical Cancer, Soft Tissue Sarcoma
- Associated Therapies
- -
Study of Single Agent Pembrolizumab (MK-3475) Versus Single Agent Chemotherapy for Metastatic Triple Negative Breast Cancer (MK-3475-119/KEYNOTE-119)
- Conditions
- Interventions
- First Posted Date
- 2015-09-21
- Last Posted Date
- 2021-12-10
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 622
- Registration Number
- NCT02555657
Metronomic Chemotherapy Based on Adaptative Bio-mathematical Model of Oral Vinorelbine in Patients With NSCLC or MPM
- Conditions
- Interventions
- First Posted Date
- 2015-09-21
- Last Posted Date
- 2022-11-17
- Lead Sponsor
- Assistance Publique Hopitaux De Marseille
- Target Recruit Count
- 30
- Registration Number
- NCT02555007
- Locations
- 🇫🇷
Assistance Publique des Hôpitaux de Marseille (CEPCM), Marseille, France
Vinorelbine/Gemcitabine Versus Vinorelbine/Cisplatin in Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2015-09-09
- Last Posted Date
- 2015-09-09
- Lead Sponsor
- Shandong Cancer Hospital and Institute
- Target Recruit Count
- 200
- Registration Number
- NCT02544243
A Phase III Trial of Pertuzumab Retreatment in Previously Pertuzumab Treated Her2-Positive Advanced Breast Cancer
- First Posted Date
- 2015-08-04
- Last Posted Date
- 2020-01-07
- Lead Sponsor
- Japan Breast Cancer Research Group
- Target Recruit Count
- 370
- Registration Number
- NCT02514681
- Locations
- 🇯🇵
Japan Breast Cancer Research Group, Chuo-ku, Nihonbashi, Koami-cho, Tokyo, Japan
🇯🇵Kumamoto University Hospital, Kumamoto City, Kumamoto, Japan
🇯🇵Aichi Cancer Center, Chikusa-ku, Aichi, Japan
Recombinant Human Endostatin Combined With NP in Neoadjuvant Chemotherapy of Stage ⅢA NSCLC
- Conditions
- Interventions
- First Posted Date
- 2015-07-14
- Last Posted Date
- 2015-07-14
- Target Recruit Count
- 30
- Registration Number
- NCT02497118
- Locations
- 🇨🇳
Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China
Recombinant Human Endostatin (EndostarTM) Injection in Treatment of Recurrent Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2015-07-03
- Last Posted Date
- 2017-07-17
- Lead Sponsor
- Xinjiang Medical University
- Target Recruit Count
- 120
- Registration Number
- NCT02489409
- Locations
- 🇨🇳
Third Affiliated Hospital of Xinjiang Medical University, Urumchi, Xinjiang, China
RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)
- Conditions
- Interventions
- First Posted Date
- 2015-07-03
- Last Posted Date
- 2022-10-03
- Lead Sponsor
- EpicentRx, Inc.
- Target Recruit Count
- 139
- Registration Number
- NCT02489903
- Locations
- 🇺🇸
Stanford University, Palo Alto, California, United States
🇺🇸Baptist Health, Lexington, Kentucky, United States
🇺🇸Memorial Hospital of South Bend, South Bend, Indiana, United States
Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010]
- Conditions
- Interventions
- First Posted Date
- 2015-07-01
- Last Posted Date
- 2024-08-20
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1280
- Registration Number
- NCT02486718
- Locations
- 🇪🇸
Hospital NisA 9 de Octubre, Valencia, Spain
🇨🇳Zhejiang Cancer Hospital, Zhejiang, China
🇫🇷Hôpital Universitaire Dupuytren, Limoges, France
Study of Docetaxel or Vinorelbine Plus Cisplatin in Neoadjuvant Chemoradiotherapy for Esophageal Cancer (NEOCRTEC308)
- Conditions
- Interventions
- First Posted Date
- 2015-06-08
- Last Posted Date
- 2024-01-16
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 610
- Registration Number
- NCT02465736
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
A Global Study to Assess the Effects of MEDI4736 (Durvalumab), Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer
- First Posted Date
- 2015-02-02
- Last Posted Date
- 2024-07-26
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 597
- Registration Number
- NCT02352948
- Locations
- 🇬🇧
Research Site, Wolverhampton, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.